Antibacterial Drugs: World Market Prospects 2012-2022

NEW YORK, Dec. 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antibacterial Drugs: World Market Prospects 2012-2022

http://www.reportlinker.com/p0739371/Antibacterial-Drugs-World-Market-Prospects-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

What are the commercial prospects for antibacterial treatments? Visiongain's report shows you potential revenue values to 2022. Find data, forecasts and discussions.

Discover sales predictions at world market, therapeutic class, product and national levels to 2022. Our report gives you business research, analysis and opinion for the treatment of bacterial infections. 

How will 20 leading products - including Levaquin, Zyvox, Avelox, Augmentin, Zosyn, Merrem, Cubicin, Primaxin and Cravit - perform to 2022? You can find potential revenues, with discussions. 

Also, receive forecast values for cephalosporin, penicillin, fluoroquinolone, macrolide and carbapenem submarkets. We analyse other agents too. See possible sales trends for antibiotics from 2012.

This study discusses Pfizer, Merck, GSK, Cubist, Abbott, Bayer and other pharmaceutical companies. Receive analyses for anti-infective agents in human healthcare, including hospital-acquired infections.

What does the future hold? With its R&D pipeline, the antimicrobial drug industry has potential for improved treatment of bacterial diseases. Bacteria still pose a great threat, with antibiotic resistance staying a challenge in clinical practice.

Visiongain's report provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You can find answers now in our work.

Revenue forecasts, market shares, developmental trends, discussions and interviews

In our report, you find revenue forecasting, growth rates, market shares, qualitative analyses (incl. SWOT and STEP), views and R&D news. You receive 149 tables and charts and two research interviews.

Advantages of Antibacterial Drugs: World Market Prospects 2012-2022for your work

In particular, our study gives you the following knowledge and benefits:

• Find revenue predictions to 2022 for the overall world antibacterial drug market and submarkets, seeing revenue growth

• Discover revenue forecasts to 2022 for 20 leading products, assessing commercial potential

• See revenue forecasts to 2022 for leading national markets - US, Japan,China, India, Brazil, France, Italy, Germany, UK and Spain

• Assess leading companies, discovering their activities and prospects

• Review R&D for treating bacterial diseases, seeing pipeline trends

• Investigate competition and opportunities influencing the sector and its sales

• Find out what will stimulate and restrain the industry and market

• View opinions from our survey, discovering interviews with industrial experts.

There, you find a distinctive mix of quantitative and qualitative work with independent predictions. We tackle crucial questions on antibacterials, helping you to stay ahead.

Gain business research, data and analysis for antibacterial agents

Our study is for everybody needing industry and market analyses for bacterial anti-infective medicine. Find data, trends and answers. Avoid missing out - please order our report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6 

Table of Contents

1. Executive Summary

1.1 Antibacterial Drugs: World Market Review

1.2 Chapter Breakdown

1.3 Research and Analysis Methods

2. An Introduction to Bacteria, Bacterial Infections and Antibacterial Drugs

2.1 Bacteria and Bacterial Infections

2.1.1 Bacteria

2.1.2 Clinically Important Bacteria

2.1.3 Bacterial Infections

2.1.3.1 Bacteria's Infectious Activity

2.2 Antibacterial Drugs

2.2.1 A History of Antibacterial Drugs

2.2.1.1 Penicillin

2.2.1.2 Other Key Steps in the History of Antibacterial Drugs

2.2.2 Mechanisms of Action for Antibacterial Drugs

3. The Antibacterial Drugs Market 2012-2022

3.1 The Antibacterial Drugs Market 2010-2011

3.2 The Antibacterial Drugs Market: Overall Revenue Forecast 2012-2022

3.2.1 Generic Competition

3.2.2 Prescribing Antibacterial Drugs

3.2.3 Bacterial Resistance

3.2.4 R&D Pipeline Will Restrain Growth?

3.3 Cephalosporins Submarket 2010-2011

3.3.1 Cephalosporins Submarket: Revenue Forecast 2012-2022

3.4 Penicillin Submarket 2010-2011

3.4.1 Penicillins Submarket: Revenue Forecast 2012-2022

3.5 Fluoroquinolone Submarket 2010-2011

3.5.1 Fluoroquinolones are Linked with Side Effects

3.5.2 Fluoroquinolone Pipeline 2011

3.5.3 Fluoroquinolone Submarket: Revenue Forecast 2012-2022

3.6 Macrolide Submarket 2010-2011

3.6.1 Dificid: A New Macrolide

3.6.2 Macrolide Submarket: Revenue Forecast 2012-2022

3.7 Carbapenems Submarket 2010-2011

3.7.1 Doribax (Doripenem, Ortho-McNeil/Shionogi)

3.7.2 Carbapenems Submarket: Revenue Forecast 2012-2022

3.8 Other Antibacterial Drugs Submarket 2010-2011

3.8.1 Vibativ

3.8.2 Other Antibacterial Drugs Submarket: Revenue Forecast 2012-2022

4. Leading Antibacterial Drugs: Market Prospects to 2022

4.1 Leading Antibacterial Drugs Overview

4.2 Levaquin

4.2.1 Levaquin: Revenue Forecast 2012-2022

4.3 Zyvox

4.3.1 Zyvox: Revenue Forecast 2012-2022

4.4 Avelox

4.4.1 Avelox: Revenue Forecast 2012-2022

4.5 Augmentin

4.5.1 Augmentin: Revenue Forecast 2012-2022

4.6 Zosyn

4.6.1 Zosyn: Revenue Forecast 2012-2022

4.7 Merrem

4.7.1 Merrem: Revenue Forecast 2012-2022

4.8 Cubicin

4.8.1 Cubicin: US Revenue Forecast 2012-2022

4.9 Primaxin

4.9.1 Primaxin: Revenue Forecast 2012-2022

4.10 Biaxin

4.11 Cravit

4.11.1 Cravit: Revenue Forecast 2012-2022

4.12 Zithromax

4.13 Invanz

4.13.1 Invanz: Revenue Forecast 2012-2022

4.14 Cipro

4.15 Tygacil

4.15.1 Tygacil: Revenue Forecast 2012-2022

4.16 Rocephin

4.16.1 Rocephin: Revenue Forecast 2012-2022

4.17 Zinnat

4.18 Flomox

4.19 Unasyn

4.20 Dalacin C

4.21 Meiact

5. Leading National Antibacterial Drug Markets 2012-2022

5.1 Leading National Markets 2010-2011

5.2 Leading National Markets: Revenue Forecasts 2012-2022

5.3 The European Market: Revenue Forecasts 2012-2022

5.4 The US: Revenues 2012-2022

5.5 China: Revenues 2012-2022

5.6 Japan: Revenues 2012-2022

5.7 India: Revenues 2012-2022

5.8 Brazil: Revenues 2012-2022

6. Antibacterial Drugs R&D Pipeline in 2011

6.1 Zinforo (Ceftaroline, AstraZeneca/Forest Laboratories)

6.2 Ceftobiprole (Basilea Pharmaceutica)

6.3 Restanza (Cethromycin, Advanced Life Sciences): Any Future Development?

6.4 Dalbavancin (Durata Therapeutics)

6.5 Nuvocid (Oritavancin, The Medicines Company)

6.6 TR-701 (Tedizolid, Trius Therapeutics)

6.7 CAZ104 (Ceftazidime/Avibactam, AstraZeneca/Forest Laboratories)

6.7.1 CEF104 (Ceftaroline/Avibactam, AstraZeneca/Forest Laboratories)

6.8 CXA-201 (Cubist)

6.9 NKTR-061 (Amikacin Inhalation, Bayer/Nektar Therapeutics)

6.10 Ramoplanin (Nanotherapeutics)

6.11 Radezolid (Rib-X Pharmaceuticals)

7. Antibacterial Drugs: Industry Trends 2012-2022

7.1 Strengths and Weaknesses in the Antibacterial Drugs Market 2011

7.2 Opportunities and Threats in the Antibacterial Drugs Market 2012-2022

7.3 Late-Stage Pipeline Therapies

7.3.1 Governmental Incentives

7.4 New Strategies

7.4.1. Monoclonal Antibodies

7.4.2 Inhaled Antibiotics for Hospital-Acquired Pneumonia

7.5 Bacterial Resistance: An Opportunity and a Threat

7.5.1 Emerging Resistance

7.5.2 Restricting Drug Use

7.6 The Challenge of Non-Inferiority Trials

7.7 Improved Regulatory Guidance

7.8 Lifecycle Management

7.9 Hospital-Acquired Infections

7.9.1 Treating Hospital-Acquired Infections

7.9.2 Preventing Hospital-Acquired Infections

7.9.3 Hospital Hygiene

7.9.4 Tracking Infections

7.9.5 Advances in Hospital Equipment

7.9.5.1 Copper Kills Bacteria

8. Research Interviews8.1 Professor Malcolm Page, Head of Biology, Basilea Pharmaceutica

8.1 Professor Malcolm Page, Head of Biology, Basilea Pharmaceutica

8.1.1 Basilea Pharmaceutica

8.1.2 Antibacterial Research This Decade

8.1.3 Challenges in Developing Treatments for Gram-Negative Bacteria

8.1.4 Overcoming Drug Resistance

8.1.5 New Targets for Antibacterial Drug Development

8.2 Dr Michael Rudolf, CSO, Kenta Biotech

8.2.1 Kenta Biotech

8.2.2 Monoclonal Antibodies for Bacterial Infections

8.2.3 Challenges in Developing Treatments for Gram-Negative Bacteria

8.2.4 Unmet Needs in the Antibacterial Drugs Market

9. Conclusions from Our Study

9.1 Antibacterial Drugs Market 2012-2022

9.1.1 Leading Product Performance 2012-2022

9.2 The R&D Pipeline: Outlook for the Future

9.3 Bacterial Resistance: a Rising Challenge

Other Content

Glossary: Clinical Bacteriology

List of Tables

Table 1.1 Currency Exchange Rates

Table 1.2 Common Abbreviations Used in this Report

Table 2.1 Common Causes of Hospital-Acquired Infections Worldwide, 2011

Table 2.2 Examples of Clinically-Important Bacteria, 2011

Table 2.3 Mechanism of Action for Leading Antibacterial Drug Classes

Table 3.1 Antibacterial Drugs Market by Class, 2010

Table 3.2 Antibacterial Drugs Market: Overall Market and Revenue Forecasts by Class, 2010-2022

Table 3.3 Antibacterial Drugs Market: Drivers and Restraints, 2012-2022

Table 3.4 Antibacterial Drugs: Submarket Shares, 2010-2022

Table 3.5 Cephalosporins Submarket: Drug Revenues, 2010

Table 3.6 Cephalosporins Submarket: Revenue Forecast, 2010-2022

Table 3.7 Cephalosporins Submarket: Drivers and Restraints, 2012-2022

Table 3.8 Penicillins Submarket: Drug Revenues, 2010

Table 3.9 Penicillins Submarket: Drivers and Restraints, 2012-2022

Table 3.10 Penicillins Submarket: Revenue Forecast, 2010-2022

Table 3.11 Fluoroquinolones Submarket: Drug Revenues, 2010

Table 3.12 Penicillins Submarket: Drivers and Restraints, 2012-2022

Table 3.13 Fluoroquinolones Submarket: Revenue Forecast, 2010-2022

Table 3.14 Macrolides Submarket: Drug Revenues, 2010

Table 3.15 Macrolides Submarket: Drivers and Restraints, 2012-2022

Table 3.16 Macrolides Submarket: Revenue Forecast, 2010-2022

Table 3.17 Carbapenems Submarket: Drug Revenues, 2010

Table 3.18 Carbapenems Submarket: Drivers and Restraints, 2012-2022

Table 3.19 Carbapenems Submarket: Revenue Forecast, 2010-2022

Table 3.20 Other Antibacterial Drugs Submarket: Drug Revenues, 2010

Table 3.21 Other Antibacterial Drugs Submarket: Revenue Forecast, 2010-2022

Table 4.1 Top 20 Antibacterial Drugs, 2010

Table 4.2 2010 Top 20 Antibacterial Drugs: Revenue Forecast, 2010-2022

Table 4.3 Levaquin Key Facts, 2011

Table 4.4 Levaquin: Revenue Forecast, 2010-2022

Table 4.5 Zyvox Key Facts, 2011

Table 4.6 Zyvox: Nine-Month Revenue, 2010-2011

Table 4.7 Zyvox: Revenue Forecast, 2010-2022

Table 4.8 Avelox Key Facts, 2011

Table 4.9 Avelox: Six-Month Revenue by Company, 2010-2011

Table 4.10 Avelox: Revenue Forecast, 2010-2022

Table 4.11 Augmentin Key Facts, 2011

Table 4.12 Augmentin: Revenue Forecast, 2010-2022

Table 4.13 Zosyn Key Facts, 2011

Table 4.14 Zosyn: Nine-Month Revenue, 2010-2011

Table 4.15 Zosyn: Revenue Forecast, 2010-2022

Table 4.16 Merrem Key Facts, 2011

Table 4.17 Merrem: Nine-Month Revenue, 2010-2011

Table 4.18 Merrem: Revenue Forecast, 2010-2022

Table 4.19 Cubicin Key Facts, 2011

Table 4.20 Cubicin: Nine-Month Revenue, 2010-2011

Table 4.21 Cubicin: Revenue Forecast, 2010-2022

Table 4.22 Primaxin Key Facts, 2011

Table 4.23 Primaxin: Revenue Forecast, 2010-2022

Table 4.24 Biaxin Key Facts, 2011

Table 4.25 Biaxin: Revenue Forecast, 2010-2022

Table 4.26 Cravit Key Facts, 2011

Table 4.27 Cravit: Revenue, Fiscal Years 2006-2011

Table 4.28 Cravit: Revenue Forecast, 2010-2022

Table 4.29 Zithromax Key Facts, 2011

Table 4.30 Zithromax: Nine-Month Revenue, 2010-2011

Table 4.31 Zithromax: Revenue Forecast, 2010-2022

Table 4.32 Invanz Key Facts, 2011

Table 4.33 Invanz: Six-Month Revenue, 2010-2011

Table 4.34 Invanz: Revenue Forecast, 2010-2022

Table 4.35 Cipro Key Facts, 2011

Table 4.36 Cipro: Revenue Forecast, 2010-2022

Table 4.37 Tygacil Key Facts, 2011

Table 4.38 Tygacil: Nine-Month Revenue, 2010-2011

Table 4.39 Tygacil: Revenue Forecast, 2010-2022

Table 4.40 Rocephin Key Facts, 2011

Table 4.41 Rocephin: Revenue Forecast, 2010-2022

Table 4.42 Zinnat Key Facts, 2011

Table 4.43 Zinnat: Revenue Forecast, 2010-2022

Table 4.44 Flomox Key Facts, 2011

Table 4.45 Flomox: Revenue Forecast, 2010-2022

Table 4.46 Unasyn Key Facts, 2011

Table 4.47 Unasyn: Revenue Forecast, 2010-2022

Table 4.48 Dalacin C Key Facts, 2011

Table 4.49 Dalacin C: Revenue Forecast, 2010-2022

Table 4.50 Meiact Key Facts, 2011

Table 4.51 Meiact: Revenue Forecast, 2010-2022

Table 5.1 Antibacterial Drugs Market by Region, 2010

Table 5.2 Antibacterial Drugs Market: Revenue Forecasts by Region, 2010-2022

Table 5.3 European Antibacterial Drugs Market by Country, 2010

Table 5.4 European Antibacterial Drugs Market: Revenue Forecasts by Country, 2010-2022

Table 6.1 Selected Antibacterial Pipeline Candidates Discussed

Table 6.2 Selected Antibacterial Pipeline Candidates Not Discussed

Table 7.1 Antibacterial Drugs Market: Strength and Weaknesses, 2011

Table 7.2 Antibacterial Drugs Market: Opportunities and Threats, 2012-2022

Table 7.3 Selected Inhaled Antibiotics in Development, 2011

Table 9.1 Antibacterial Drugs Market: Revenues by Class, 2010, 2016 and 2022

Table 9.2 Fate of the 2010 Top 20 Antibacterial Drugs: Combined Revenues, 2010, 2016 and 2022

List of Figures

Figure 2.1 Milestones in the History of Antibacterial Agents, 1940-2011

Figure 3.1 Antibacterial Drugs: Market Shares by Class, 2010

Figure 3.2 Antibacterial Drugs Market: Overall Market and Revenue Forecasts by Class, 2010-2022

Figure 3.3 Antibacterial Drugs: Market Shares by Class, 2016

Figure 3.4 Antibacterial Drugs: Market Shares by Class, 2022

Figure 3.5 Cephalosporins Submarket: Market Shares, 2010

Figure 3.6 Cephalosporins Submarket: Revenue Forecast, 2010-2022

Figure 3.7 Penicillins Submarket: Market Shares, 2010

Figure 3.8 Penicillins Submarket: Revenue Forecast, 2010-2022

Figure 3.9 Fluoroquinolones Submarket: Market Shares, 2010

Figure 3.10 Fluoroquinolones Submarket: Revenue Forecast, 2010-2022

Figure 3.11 Macrolides Submarket: Market Shares, 2010

Figure 3.12 Macrolides Submarket: Revenue Forecast, 2010-2022

Figure 3.13 Carbapenems Submarket: Market Shares, 2010

Figure 3.14 Carbapenems Submarket: Revenue Forecast, 2010-2022

Figure 3.15 Other Antibacterial Drugs Submarket: Market Shares, 2010

Figure 3.16 Other Antibacterial Drugs Submarket: Revenue Forecast, 2010-2022

Figure 4.1 Top 20 Antibacterial Drugs, 2010

Figure 4.2 2010 Top 20 Antibacterial Drugs: Grouped Revenue Forecast, 2010-2022

Figure 4.3 Levaquin: Revenue Forecast, 2010-2022

Figure 4.4 Zyvox: Nine-Month Revenue, 2010-2011

Figure 4.5 Zyvox: Revenue Forecast, 2010-2022

Figure 4.6 Avelox: Six-Month Revenue by Company, 2010-2011

Figure 4.7 Avelox: Revenue Forecast, 2010-2022

Figure 4.8 Augmentin: Revenue Forecast, 2010-2022

Figure 4.9 Zosyn: Nine-Month Revenue, 2010-2011

Figure 4.10 Zosyn: Revenue Forecast, 2010-2022

Figure 4.11 Merrem: Nine-Month Revenue, 2010-2011

Figure 4.12 Merrem: Revenue Forecast, 2010-2022

Figure 4.13 Cubicin: Nine-Month Revenue, 2010-2011

Figure 4.14 Cubicin: Revenue Forecast, 2010-2022

Figure 4.15 Primaxin: Revenue Forecast, 2010-2022

Figure 4.16 Biaxin: Revenue Forecast, 2010-2022

Figure 4.17 Cravit: Revenue, Fiscal Years 2006-2011

Figure 4.18 Cravit: Revenue Forecast, 2010-2022

Figure 4.19 Zithromax: Nine-Month Revenue, 2010-2011

Figure 4.20 Zithromax: Revenue Forecast, 2010-2022

Figure 4.21 Invanz: Six-Month Revenue, 2010-2011

Figure 4.22 Invanz: Revenue Forecast, 2010-2022

Figure 4.23 Cipro: Revenue Forecast, 2010-2022

Figure 4.24 Tygacil: Nine-Month Revenue, 2010-2011

Figure 4.25 Tygacil: Revenue Forecast, 2010-2022

Figure 4.26 Rocephin: Revenue Forecast, 2010-2022

Figure 4.27 Zinnat: Revenue Forecast, 2010-2022

Figure 4.28 Flomox: Revenue Forecast, 2010-2022

Figure 4.29 Unasyn: Revenue Forecast, 2010-2022

Figure 4.30 Dalacin C: Revenue Forecast, 2010-2022

Figure 4.31 Meiact: Revenue Forecast, 2010-2022

Figure 5.1 Antibacterial Drugs Market Shares by Region, 2010

Figure 5.2 Antibacterial Drugs Market Shares by Region, 2016

Figure 5.3 Antibacterial Drugs Market Shares by Region, 2022

Figure 5.4 European Antibacterial Drugs Market Shares by Country, 2010

Figure 5.5 European Antibacterial Drugs Market: Revenue Forecasts by Country, 2010-2022

Figure 5.6 US Antibacterial Drugs Market: Revenue Forecast, 2010-2022

Figure 5.7 Chinese Antibacterial Drugs Market: Revenue Forecast, 2010-2022

Figure 5.8 Japanese Antibacterial Drugs Market: Revenue Forecast, 2010-2022

Figure 5.9 Indian Antibacterial Drugs Market: Revenue Forecast, 2010-2022

Figure 5.10 Brazilian Antibacterial Drugs Market: Revenue Forecast, 2010-2022

Figure 7.1 Non-Inferiority Trials and Biocreep: A Worst Case Scenario

Figure 9.1 Antibacterial Drugs Market: Revenues by Class, 2010, 2016 and 2022

Figure 9.2 Fate of the 2010 Top 20 Antibacterial Drugs: Revenues, 2010, 2016 and 2022 

Companies Listed

Abbott Laboratories

Acino

Adimab

Advanced Life Sciences

Agência Nacional de Vigilância Sanitária (Anvisa) [Brazil]

Aisling Capital

Alliance for the Prudent Use of Antibacterials (APUA) [US]

Alopexx Pharmaceuticals

Andrx (now part of Watson Pharmaceuticals)

APP Pharmaceuticals (a subsidiary of Fresenius Kabi)

Arsanis

Astellas Pharma

AstraZeneca

Aurobindo Pharma

Barr Pharmaceuticals (now part of Teva)

Basilea Pharmaceutica

Bayer

Bioquell

C&O Pharmaceutical Technology (Holdings)

Calixa Therapeutics (now part of Cubist Pharmaceuticals)

Canaan Partners

Cempra

Centers for Disease Control and Prevention (CDC) [US]

Centers for Medicare and Medicaid Services (CMS) [US]

Cipla

Copper Development Association [US]

Cornerstone Therapeutics

Cubist Pharmaceuticals

Daiichi Sankyo

Dainippon Sumitomo Pharma

Dr. Reddy's Laboratories

Duke University [US]

Durata Therapeutics

Eli Lilly

EMA Committee for Medicinal Products for Human Use (CHMP)

European Medicines Agency (EMA)

FDA Anti-Infective Drugs Advisory Committee (AIDAC) [US]

Food and Drug Administration (FDA) [US]

Forest Laboratories

Fresenius Kabi Pharmaceuticals

Furiex Pharmaceuticals

Future Path Medical

Gilead Sciences

Glenmark Generics

GSK

Harvard Medical School

Healthcare Infection Control Practices Advisory Committee (HICPAC) [US]

Hikma Farmaceutica

Hospira

Innocell

Insmed

Itochu Chemical Frontier

J&J

Janssen Pharmaceutica (a subsidiary of J&J)

Japan Patent Office (JPO)

KaloBios Pharmaceuticals

Kenta Biotech

King's College London

Lederle Laboratories (acquired by Wyeth, now part of Pfizer)

Lupin Pharmaceuticals

Medicines and Healthcare products Regulatory Agency (MHRA) [UK]

Meiji Seika Kaisha

Merck & Co.

Michigan State University

Ministry of Health and Family Welfare [India]

Ministry of Health, Labor and Welfare (MHLW) [Japan]

Mpex Pharmaceuticals

Mylan

Nanotherapeutics

National Health Service (NHS) [UK]

Nektar Therapeutics

New Leaf Venture Partners

Novartis

Novexel

Optimer Pharmaceuticals

Orchid Chemicals and Pharmaceuticals

Ortho-McNeil Pharmaceuticals (a subsidiary of J&J)

Oscient Pharmaceuticals

Paratek Pharmaceuticals

Parke-Davis (now part of Pfizer)

Peking University

Pfizer

Pharmaceutical Research and Manufacturers of America (PhRMA) [US]

Pharmacia (now part of Pfizer)

Pliva (now part of Teva)

RaQualia Pharma

Rib-X Pharmaceuticals

Roche

Sandoz

Sanofi

Sanofi Pasteur (part of Sanofi)

Sawai Pharmaceutical

Schering-Plough (now part of Merck & Co)

Shionogi

St Thomas' Hospital

Strides Arcolab

Sumitomo Pharmaceuticals (now part of Dainippon Sumitomo)

Takeda Pharmaceutical Company

TAP Holdings

Targanta Therapeutics (now part of The Medicines Company)

Teva Pharmaceuticals

The Medicines Company

Theravance

Trius Therapeutics

University of Birmingham [UK]

University of Pennsylvania

US Department of Defense

Vicuron Pharmaceuticals (now part of Durata Therapeutics)

Watson Pharmaceuticals

Wockhardt

World Health Organization (WHO)

Wyeth (now part of Pfizer) 

To order this report:

Drug and Medication Industry: Antibacterial Drugs: World Market Prospects 2012-2022

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker